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Background: Visual outcome of patients with neovascular age-related macular de-1 
generation has significantly improved during the last years following the introduction 2 
of anti-vascular endothelial growth factor (VEGF) therapy. However, about one third 3 
of patients show persistent exudation and decreasing visual acuity despite recurrent 4 
anti-VEGF treatment, which implies a role of other, still unknown proangiogenic me-5 
diators. 6 
Methods: The present study applied transcriptional profiling of human and mouse 7 
(C57BL/6J wildtype) choroidal neovascularization (CNV) membranes each with ref-8 
erence to healthy control tissue to identify yet unrecognized mediators of CNV for-9 
mation. Key factors were further investigated by immunohistochemistry as well as by 10 
intravitreal inhibition experiments and multiplex protein assays in the laser-induced 11 
CNV mouse model.  12 
Results: Transcriptional profiles of CNV membranes were characterized by en-13 
hanced activation of blood vessel development, cytoskeletal organization, and cyto-14 
kine production, with angiogenesis and wound healing processes predominating in 15 
humans and activation of immune processes in mice. Besides several species-16 
specific factors, 95 phylogenetically conserved CNV-associated genes were detect-17 
ed, among which fibroblast growth factor inducible-14 (FN14), a member of the tumor 18 
necrosis factor (TNF) receptor family, was identified as a key player of CNV for-19 
mation. Blocking the pathway by intravitreal injection of a FN14 decoy receptor 20 
modulated the cytokine profile - most notably IL-6 - and led to a significant reduction 21 
of CNV size in vivo.  22 
Conclusions: This study characterizes the transcriptome of human and mouse CNV 23 
membranes in an unprejudiced manner and identifies FN14 as a phylogenetically 24 
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conserved mediator of CNV formation and a promising new therapeutic target for ne-25 
ovascular AMD. 26 
Funding: This study was funded by the Helmut-Ecker-Stiftung and the Volker-27 
Homann-Stiftung.  28 
 29 
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Age-related macular degeneration (AMD) is the most common cause of permanent 31 
blindness in elderly people in developed countries. Its worldwide prevalence is esti-32 
mated to increase from 200 million in 2020 to 300 million by 2040 as a result of popu-33 
lation ageing (Wong et al., 2014). Worldwide, about 40 million people suffer from the 34 
neovascular form of AMD (nAMD) (Wong et al., 2014), which is characterized by the 35 
formation of pathological choroidal neovascularisation (CNV) leading to edema, 36 
hemorrhage, scarring and ultimately irreversible impairment of central vision (Mitchell 37 
et al., 2018). An important proangiogenic mediator in this process is the vascular en-38 
dothelial growth factor (VEGF), which increases vascular permeability and promotes 39 
the development of CNV. Within the last years, anti-VEGF therapy has significantly 40 
improved visual outcomes in nAMD (Bressler et al., 2011; Mitchell et al., 2018). 41 
However, about one third of patients with nAMD show persistent exudation and a 42 
slow decrease in visual acuity despite intensive anti-VEGF therapy (Wecker et al., 43 
2019; Yang et al., 2016). This illustrates the complexity of the disease and indicates 44 
a role of other proangiogenic mediators in the development and progression of CNV 45 
in nAMD.  46 
So far, the laser-induced CNV mouse model was extensively used to mimic the dis-47 
ease in vivo allowing the identification and evaluation of novel mediators of CNV de-48 
velopment (Bucher et al., 2020; Lange et al., 2016; Schlecht et al., 2020b; Wang et 49 
al., 2013). However, an unbiased comparison of the transcriptional landscapes be-50 
tween murine and human CNV is still lacking but of significant importance for the in-51 
terpretation of the mouse model and the translation of preclinical findings into novel 52 
clinical treatment regimens. To address the urgent need for alternative therapeutic 53 
approaches, the present study characterizes the transcriptome of human and mouse 54 
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CNV membranes each with reference to healthy control tissue, analyses the involved 55 
biological processes, and compares differentially expressed genes in order to identify 56 
conserved mediators of CNV formation. Following this approach, the study identifies 57 
fibroblast growth factor inducible-14 (FN14) as a novel key factor of CNV formation, 58 
investigates its influence on the cytokine milieu of CNV, as well as its antiangiogenic 59 
effect in vivo.  60 
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CNV membranes were obtained from four patients with neovascular AMD undergo-62 
ing the meanwhile obsolete procedure of subretinal CNV extraction (Bressler et al., 63 
2000) between 1992 and 1999. Only patients with treatment-naive classical CNV as-64 
sociated with typical AMD changes such as drusen and RPE alterations were includ-65 
ed in the study. Patients with concomitant diseases, such as myopia or central se-66 
rous chorioretinopathy, were excluded from the study. Following a 20-gauge vitrec-67 
tomy, a retinotomy was performed temporally to the macula and the CNV membrane 68 
was surgically extracted using a flexed forceps. Four age-matched RPE-choroidal 69 
samples from the macular region of four enucleated eyes suffering from ciliary body 70 
melanoma served as controls. For protein analysis, undiluted vitreous samples were 71 
obtained from further patients with nAMD (n = 6) and control patients (n = 6) who un-72 
derwent vitrectomy for subretinal bleeding or macular pucker, respectively. Ethics 73 
approval was granted from local Ethics Committees. 74 
Mice 75 
Mice used in this study were C57BL/6J wildtype mice purchased from Charles River. 76 
All animal experiments were approved by the local authority (Regierungspräsidium 77 
Freiburg, Germany) and were performed in accordance with the respective national, 78 
federal and institutional regulations. All animals were tested negatively for the Rd8 79 
(Crb1) mutation.  80 
Laser-induced choroidal neovascularization model 81 
Six to eight weeks old C57BL/6J wildtype mice were anesthetized with intraperitoneal 82 
injection of a mixture of ketamine (100 µg/g) and xylazine (12 µg/g). Pupils were di-83 
lated with a combination of tropicamide (5 mg/ml) and neosynephrine-POS (50 84 
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mg/ml). Lubricating gel was administered to protect the eye and to maintain corneal 85 
hydration. The eye was carefully placed against a cover glass to flatten the curved 86 
corneal surface. Laser burns at equal distance from the optic disc were induced by 87 
an Argon laser (VISULAS 532s, ZEISS) with a wavelength of 532 nm, a power of 150 88 
mW, a diameter of 100 µm and duration of 100 ms (Buhler et al., 2013). Only burns 89 
that produced a bubble as a sign for Bruch`s membrane rupture and without concom-90 
itant bleeding were included in the study (Tobe et al., 1998). After laser treatment, 91 
mice were placed on a prewarmed warming plate at 35 °C until they recovered from 92 
anesthesia.  93 
Intravitreal injection of a FN14 decoy receptor and quantification of CNV lesion 94 
size 95 
Laser-induced choroidal neovascularization (CNV) was induced at day 0 (d0) in 96 
C57BL/6J wildtype mice as described above. At d1 mice received an intravitreal in-97 
jection of 4 µg FN14 decoy receptor (1610-TW, R&D Systems) dissolved in 1 µl PBS 98 
in one eye and the same volume of PBS in the other eye. Injections were performed 99 
with a Nanofil 10 µl syringe using a Nanofil 34 G needle (World Precision Tools, Sar-100 
asota, USA) under microscopic visual control. At d7, fundus photography and fluo-101 
rescein angiography (ALCON Fluorescein 10 %, diluted 1:20 with 0.9 % NaCl, intra-102 
peritoneal injection of 40 µL per 20 g mouse) were performed using a retinal imaging 103 
microscope (Micron IV, Phoenix Technology Group, Pleasanton, USA). To quantify 104 
CNV size, RPE/choroidal flatmounts were dissected and stained (see section below) 105 
and fluorescence images (647 nm, COL4) of the entire RPE/choroid were taken us-106 
ing a Hamamatsu NanoZoomer S60 (Hamamatsu Photonics, Herrsching, Germany). 107 
Spot sizes were determined by a masked investigator. Confluent lesions and animals 108 
with vitreal or subretinal hemorrhage were excluded from further analysis. Each inhi-109 
bition experiment was independently performed twice.  110 
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Sample preparation for RNA sequencing 111 
An illustration of the experimental setup for transcriptional characterization of human 112 
and mouse CNV is shown in Figure 1A. For transcriptomic characterization of human 113 
CNV membranes, RNA sequencing data generated and recently published by our 114 
group (Schlecht et al., 2020a) were reanalyzed as described below. FFPE pro-115 
cessing was performed immediately after resection according to routine protocols, as 116 
described previously (Lange et al., 2018; Schlecht et al., 2020a). Following routine 117 
histological staining, each specimen’s histological diagnosis was made by two expe-118 
rienced ophthalmic pathologists. Fifteen FFPE sections of 4 µm thickness from each 119 
CNV membrane and each central RPE-choroid complex were stored in tubes prior to 120 
RNA extraction, as previously described (Schlecht et al., 2020a). 121 
For transcriptome analysis of mouse CNV membranes, CNV was induced in six 122 
C57BL/6J wildtype mice with six laser spots per eye at d0, as described above. Six 123 
mice without laser treatment served as controls. At d7, fundus photography was per-124 
formed (Micron IV, Phoenix Technology Group, Pleasanton, USA) and mice were 125 
sacrificed by cervical dislocation. After enucleation, the eyes were immediately fixed 126 
in 4 % formaldehyde for 2 h at room temperature (RT) as previously described 127 
(Lange et al., 2018; Schlecht et al., 2020a) followed by extensive washing in PBS. 128 
Subsequently, central RPE and choroid were dissected in PBS. FFPE RPE-choroid 129 
samples from both eyes of one animal were pooled and stored in tubes prior to RNA 130 
extraction. In addition, routine hematoxylin and eosin staining was performed on 4 131 
µm sections of FFPE processed eyes of the laser and control group. FFPE pro-132 
cessing was kept identical for human and mouse samples to ensure methodological 133 
comparability. 134 
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RNA isolation 135 
RNA isolation from FFPE specimens was carried out as previously described (Lange 136 
et al., 2018; Schlecht et al., 2020a). Briefly, total RNA was extracted from FFPE 137 
samples using the Quick-RNA FFPE Kit (Zymo Research, Irvine, California). Follow-138 
ing DNAse I digestion using the Baseline-ZERO Kit (Epicentre, Madison, Wisconsin), 139 
the RNA concentration was quantified using the Qubit RNA HS Assay Kit on a Qubit 140 
Fluorometer (Life Technologies, Carlsbad, California). RNA quality was determined 141 
via the RNA Pico Sensitivity Assay on a LabChip GXII Touch (PerkinElmer, Waltham, 142 
Massachusetts). 143 
MACE RNA-Sequencing 144 
RNA sequencing was performed using massive analysis of cDNA ends (MACE), a 3’ 145 
RNA sequencing method, as previously described (Schlecht et al., 2020a; Wolf et al., 146 
2020). We recently demonstrated that MACE allows sequencing of FFPE samples 147 
with high accuracy independent of storage time (Boneva et al., 2020). Briefly, 20 bar-148 
coded libraries comprising unique molecule identifiers (six mouse CNV membranes, 149 
six mouse RPE-choroidal control samples, four human CNV membranes and four 150 
human RPE-choroidal control tissues) were sequenced on the NextSeq 500 (Illumi-151 
na) with 1 × 75 bp. PCR bias was removed using unique molecular identifiers. 152 
Bioinformatics 153 
Sequencing data (fastq-files) were uploaded to the Galaxy web platform (usegal-154 
axy.eu) (Afgan et al., 2018), as previously described (Boeck et al., 2020). Quality 155 
control was performed with FastQC Galaxy Version 0.72 156 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ last access on 157 
08/04/2019). Reads were mapped to the human (hg38) or mouse (mm10) Galaxy 158 
built-in reference genome with RNA STAR Galaxy Version 2.6.0b-2 (Dobin et al., 159 
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2013) using Gencode annotation files (human: Gencode 31, release June 2019, 160 
https://www.gencodegenes.org/human/releases.html, mouse: Gencode M22, release 161 
June 2019, https://www.gencodegenes.org/mouse/releases.html). Reads mapped to 162 
the human or mouse reference genome were counted using featureCounts (Galaxy 163 
Version 1.6.4) (Liao et al., 2014) using the aforementioned annotation files. The out-164 
puts of featureCounts were imported to RStudio (Version 1.2.1335, R Version 3.5.3). 165 
Gene symbols and gene types were determined based on the ENSEMBL database 166 
(human genes, GRCh38.p12, download on 08/31/2019, mouse genes GRCm38.p6, 167 
download on 08/25/2019) (Zerbino et al., 2018). Orthologous genes were determined 168 
based on ENSEMBL one-to-one orthologs (download on 10/03/2019). After principle 169 
component analysis (Love et al., 2014), differential gene expression was analyzed 170 
using the R package DESeq2 1.22.2 with default parameters (Benjamini-Hochberg 171 
adjusted p-value) (Love et al., 2014). Transcripts with log2fold change (log2FC) > 0.5 172 
or < -0.5 and adjusted p-value < 0.05 were considered as differentially expressed 173 
genes (DEG) (Schurch et al., 2016). Heatmaps were created with the R package 174 
ComplexHeatmap 1.20.0 (Gu et al., 2016). Gene enrichment analysis and its visuali-175 
zation with dotplots and cnetplots was done using the R package clusterProfiler 176 
3.10.1 (Yu et al., 2012). Other data visualization was performed using the ggplot2 177 
package (Wickham, 2016). The percentage of upregulated genes involved in dis-178 
ease-relevant biological processes was determined based on lists of genes associat-179 
ed with the GO-terms angiogenesis (GO:0001525), blood vessel development 180 
(GO:0001568) (combined to angiogenesis), immune response (GO:0006955) and 181 
response to wounding (GO:0009611) for human and mouse separately (download 182 
from http://geneontology.org (The Gene Ontology, 2019), on 10/21/2019). The se-183 
quencing data have been deposited to the Gene Expression Omnibus database un-184 
der the accession number GSE163090. 185 
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Mice were sacrificed by transcardial perfusion with phosphate-buffered saline (PBS) 187 
and 4 % paraformaldehyde (PFA) for 1 min each (10 ml/min, 4 °C). After enucleation, 188 
the eyes were immediately fixed in 4 % PFA for 1 h at 4 °C followed by extensive 189 
washing with PBS. Subsequently, flatmounts of retina and RPE/choroid were dis-190 
sected in PBS. Flatmounts were then blocked and permeabilized with PBS contain-191 
ing 1 % bovine serum albumin (BSA) and 0.3 % Triton-X 100 overnight. Primary anti-192 
bodies against Collagen IV (COL4, AB769, Merck Millipore, Billerica, MA, USA) and 193 
AIF1 (also known as IBA1, AB178846, Abcam, Cambridge, United Kingdom) in PBS 194 
containing 1 % BSA and 0.3 % Triton-X 100 were added over two nights at a dilution 195 
of 1:500 at 4 °C. After extensive washing with PBS containing 0.5 % BSA and 0.15 % 196 
Triton-X 100, secondary antibodies were added at a dilution of 1:500 (Alexa Fluor 197 
647 donkey anti-goat (A21447), and Alexa Flour 568 donkey anti-rabbit (A10042), 198 
Thermo Fisher Scientific, Waltham, USA) overnight at 4 °C in the dark. After exten-199 
sive washing with PBS, samples were mounted in Fluorescence Mounting Medium 200 
(Agilent Dako, Santa Clara, California, USA). 201 
For cryosections, eyes were immediately fixed in 4 % PFA for 1 h at 4 °C followed by 202 
extensive washing in PBS. After corneotomy and lentectomy, eyes were dehydrated 203 
in 20 % sucrose overnight at 4 °C and embedded in Tissue-Tek O.C.T. Compound 204 
(Sakura Finetek Germany GmbH). Following extensive washing with PBS, 12 µm 205 
sections were blocked and permeabilized with PBS containing 1 % BSA and 0.3 % 206 
Triton-X 100 for 1 hour. Primary antibodies against FN14 (dilution: 1:500, ab109365, 207 
Abcam, Cambridge, United Kingdom), COL4 (dilution: 1:100, AB769, Merck Millipore, 208 
Billerica, MA, USA), AIF1 (dilution: 1:1000, ab178846, Abcam, Cambridge, United 209 
Kingdom) and rabbit monoclonal IgG isotype control (same concentration as FN14 210 
antibody: 0.59 µg/µl, dilution: 1:500, ab172730, Abcam, Cambridge, United Kingdom) 211 
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were incubated in PBS containing 1 % BSA and 0.3 % Triton-X 100 overnight at 4°C. 212 
For the negative control the primary antibody was omitted. Following extensive wash-213 
ing with PBS, secondary antibodies were incubated in PBS containing 1 % BSA and 214 
0.3 % Triton-X 100 at a dilution of 1:500 (Alexa Fluor 488 donkey anti-rabbit 215 
(A21206) and 647 donkey anti-goat (A21447), Thermo Fisher Scientific, Waltham, 216 
USA) for 1 hour at RT in the dark. After extensive washing with PBS, nuclei were 217 
stained with 4′,6-Diamidin-2-phenylindol (DAPI) 1:1000 in PBS for 10 min at room 218 
temperature in the dark, washed again with PBS and mounted in Fluorescence 219 
Mounting Medium (Agilent Dako, Santa Clara, California, USA). Images were taken 220 
using a Leica SP8 confocal microscope (Leica, Wetzlar, Germany) equipped with a 221 
20x NA 0.75 CS2 objective. 222 
For Immunohistochemistry on human samples, human choroidal CNV-membranes 223 
from the Eye Center, University of Freiburg, and control FFPE samples from body 224 
donors at the Institute of Anatomy, Leipzig University, were used for immunohisto-225 
chemistry. Eyes were enucleated in accordance with the consent of the body donors, 226 
which was secured by contract during lifetime, and no other data than age, sex, body 227 
weight and cause of death were disclosed. Eyes were fixed with 4 % PFA for 16 h at 228 
4 °C and dissected under a binocular microscope. Paraffin embedding was per-229 
formed using a standard protocol and 7 µm sections were obtained. Subsequently, 230 
paraffin sections were deparaffinized in accordance with a standard protocol and 231 
blocked with 2 % BSA and 2 % normal donkey serum (NDS) in PBS Triton-X 0.1 % 232 
for 60 min at RT. Primary antibodies were added at a dilution of 1:500 for FN14 233 
(ab109365, Abcam, Cambridge, United Kingdom), 1:500 for AIF1 (234-013, Synaptic 234 
Systems) and 1:200 for Collagen IV (AB769, Millipore) in PBS containing 2 % BSA 235 
and 2 % NDS in PBS Triton-X 0.1 % overnight at 4 °C. Following extensive washing 236 
with 2 % BSA and 0.2 % NDS in PBS Triton-X 0.1 %, secondary antibodies were 237 
.CC-BY 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 




added at a dilution of 1:500 (Alexa Fluor® 568 and Alexa Fluor® 647, Thermo Fisher 238 
Scientific) in PBS Triton-X 0.1% at RT for 90 min in the dark. After washing at least 239 
three times with 2 % BSA and 0.2 % NDS in PBS Triton-X 0.1 %, slides were coun-240 
terstained with DAPI 1:10000 for 10 min, washed three times with PBS followed by 241 
autofluorescence quenching with TrueBlack® Lipofuscin Autofluorescence Quencher 242 
(Biotium) according to the manufacturer’s instructions. Slides were imaged using a 243 
confocal Fluoview FV1000 (Olympus) equipped with 20x 0.75 NA U Plan S Apo and 244 
40x NA U Plan S objectives (Olympus). 245 
ELISA 246 
FN14 is one of the main receptors of TWEAK (tumor necrosis factor related weak 247 
inducer of apoptosis). TWEAK concentration in human and murine CNV compared to 248 
the respective control tissue was determined by ELISA. For human CNV, undiluted 249 
vitreous samples were obtained from six patients with nAMD and six control patients 250 
who underwent vitrectomy for subretinal bleeding or macular pucker, respectively. 251 
Plasma samples were collected by venous puncture from the same patients at the 252 
time of surgery. The vitreous and blood samples were centrifuged for 20 min at 4 °C 253 
at 500 g and 15 min at 4 °C at 2000 g, respectively and were then transferred directly 254 
into sterile plastic tubes on ice. The samples were aliquoted and stored at -80 °C until 255 
analysis. Frozen vitreous and plasma samples were thawed and TWEAK levels were 256 
measured by using a human TWEAK ELISA kit (LS-F36324, LSBio) according to the 257 
manufacturer’s instructions. For mouse, CNV was induced in six C57BL/6J wildtype 258 
mice with six laser spots per eye at d0 as described above. Another six mice without 259 
CNV induction served as control. At d7, mice were sacrificed by cervical transloca-260 
tion. After enucleation, central RPE/choroid and retina were dissected and immedi-261 
ately frozen at -80 °C. Central RPE/choroid and retinae of both eyes of each animal 262 
were pooled for further analysis. Proteins were isolated from RPE/choroid as well as 263 
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from retinal tissue of laser-treated and control mice using RIPA buffer (R0278, Sig-264 
ma-Aldrich, St. Louis, Missouri, USA) containing protease (Complete Tablets Mini, 265 
0463159001, Roche, Basel, Switzerland) and phosphatase inhibitors (Phosstop, 266 
04906845001, Roche, Basel, Switzerland). Protein concentration was evaluated by a 267 
colorimetric assay (PierceTM BCA Protein Assay Kit, 23225, Thermo Fisher Scien-268 
tific). A mouse TWEAK ELISA kit (LS-F32111, LSBio) was used to determine 269 
TWEAK concentrations in RPE/choroid and retinal samples according to the manu-270 
facturer's instructions.  271 
Multiarray protein analysis 272 
At d0 six laser spots were induced per eye in six mice, as described above. At d1 273 
mice received an intravitreal injection of 4 µg FN14 decoy receptor (1610-TW, R&D 274 
Systems) solved in 1 µl PBS in one eye and the same volume of PBS in the other 275 
eye, as described above. Another five mice without CNV induction served as control. 276 
At d5, mice were sacrificed by cervical translocation. After enucleation, central 277 
RPE/choroid and retina were dissected and immediately frozen at -80 °C. Proteins 278 
were isolated from RPE/choroid as well as from retinal tissue of laser-treated and 279 
control mice as described above (ELISA). Protein concentration was evaluated by a 280 
colorimetric assay (PierceTM BCA Protein Assay Kit, 23225, Thermo Fisher Scien-281 
tific). A multiarray electrochemiluminescence panel (U-Plex, Meso Scale Discovery, 282 
Rockville, Maryland, USA) was used to determine protein concentrations in 283 
RPE/choroid and retinal samples according to the manufacturer's instructions. The 284 
following proteins were simultaneously measured with the kit: interleukin (IL) 6, IL-33, 285 
C-X-C motif chemokine ligand (CXCL) 2, CXCL10, CC-chemokine ligand (CCL) 2, 286 
CCL5, matrix metallopeptidase 9 (MMP9), tumor necrosis factor-alpha (TNFa) and 287 
Vascular Endothelial Growth Factor A (VEGFA). 288 
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Statistical analysis was performed using RStudio (Version 1.2.1335, R Version 290 
3.5.3). Data were tested for normality applying the Kolmogorov–Smirnov test. If nor-291 
mality was given, an unpaired t-test or one-way ANOVA was applied, if not indicated 292 
otherwise. If the data did not meet the criteria of normality, the Mann–Whitney U test 293 
was applied. To compare CNV sizes between two groups, a paired Mann-Whitney U 294 
test was applied. Differences were considered significant when p value < 0.05. 295 
Study approval 296 
For human samples, ethics approval was granted from local Ethics Committees. Writ-297 
ten informed consent was received from participants prior to inclusion in the study. 298 
Participants were identified by number, not by name. All animal experiments were 299 
approved by the local authority (Regierungspräsidium Freiburg, Germany) and were 300 
performed in accordance with the respective national, federal and institutional regula-301 
tions. 302 
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Transcriptional characterization of human and mouse CNV 303 
Transcriptional profiling identified 3043 and 2379 differentially expressed genes 304 
(DEG) in human and mouse CNV, when compared to the respective control tissue 305 
(Fig. 1A, B). An orthologous gene of the other species was found in the majority of all 306 
DEG (n = 4305, 87.4 %), whereas no orthologous gene existed for 606 (12.3 %) 307 
mouse and 15 (0.3 %) human DEG (Fig. 1B). Among the orthologous genes, about 308 
half were regulated in the same direction in both species, whereas the other half was 309 
expressed inversely (Fig. 1B). 310 
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Figure 1: Experimental setup for transcriptional characterization of human and mouse CNV. (A) Representative 
fundus photography (upper panel) and hematoxylin eosine stainings (lower panel) of human and mouse CNVs 
and controls. A representative tissue area used for RNA sequencing is indicated by dashed boxes (lower panel). 
Abbreviations: AMD: age-related macular degeneration, CH: choroid, CNV: choroidal neovascularization, ONL: 
outer nuclear layer, RP: retinal pigment epithelium. (B) Supervised heatmap of differentially expressed genes 
(DEG) between CNV and control samples of both species. Each column represents one sample and each row 
one DEG. Among the 4926 DEGs there was a one-to-one ortholog of the other species for 4305 genes (87.4 %) 
(no orthologous gene for 606 (12.3 %) mouse and 15 (0.3 %) human DEGs, see Heatmap annotation to the right). 
The z-score represents a gene’s expression in relation to its mean expression by standard deviation units (red: 
upregulation, blue: downregulation). 
A closer look at the differentially expressed genes revealed that several known CNV-311 
associated factors were among the upregulated genes in both species, such as 312 
MMP9 (Matrix Metallopeptidase 9), PDGFB (Platelet Derived Growth Factor Subunit 313 
B) and AIF1 (Allograft Inflammatory Factor 1, IBA1) in human CNV (Fig. 2A) and 314 
Cx3cr1 (C-X3-C Motif Chemokine Receptor 1), Iqgap1 (IQ Motif Containing GTPase 315 
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Activating Protein 1) and Aif1 in murine CNV (Fig. 2B). In addition, S100A8 (S100 316 
calcium binding protein A8), S100A9 and MALAT1 (Metastasis Associated Lung Ad-317 
enocarcinoma Transcript 1) were among the five most upregulated genes in human 318 
CNV (Fig. 2A), while Gnat1 (G Protein Subunit Alpha Transducin 1), Sag (S-Antigen 319 
Visual Arrestin) and Slc17a7 (Solute Carrier Family 17 Member 7) were among the 320 
five most upregulated genes in mouse CNV (Fig. 2B). Gene ontology (GO) analysis 321 
revealed that upregulated genes in human CNV were mainly involved in biological 322 
processes such as blood vessel development, response to wounding, actin cytoskel-323 
eton organization and immune processes like myeloid leukocyte activation and cyto-324 
kine production (Fig. 2C). In mouse CNV membranes, upregulated genes were pre-325 
dominantly associated to synapse organization, cytokine production, actin cytoskele-326 
ton organization and blood vessel development (Fig. 2E). Looking at the proportion of 327 
CNV specific genes associated to a disease-relevant biological process, a higher 328 
percentage of upregulated genes in human CNV was involved in angiogenesis (8.4 329 
%) and wounding (6.9 %) compared to mouse CNV (4.8 % and 0.5 %, respectively). 330 
In contrast, mouse CNV was characterized by a higher proportion of immune-related 331 
genes (10.2 % vs. 4.4 %, Fig. 2D). Analyzing the factors involved in blood vessel de-332 
velopment in both species, the top five expressed genes were APOE (apolipoprotein 333 
E), COL1A1 (collagen type I alpha 1 chain), COL1A2 (collagen type I alpha 2 chain), 334 
GPX1 (glutathione peroxidase 1) and SPARC (secreted protein acidic and cysteine 335 
rich) in human CNV (Fig. 2F) and Hspg2 (heparan sulfate proteoglycan 2), Mfge8 336 
(milk fat globule-EGF factor 8 protein), Tnfrsf1a (tumor necrosis factor receptor su-337 
perfamily, member 1a), Adam15 (a disintegrin and metallopeptidase domain 15) and 338 
Col4a2 (collagen, type IV, alpha 2) in murine CNV (Fig. 2G). Among the genes asso-339 
ciated to cytokine production, S100A9, CD74, CYBA (cytochrome b-245 alpha 340 
chain), FN1 (fibronectin 1) and RPS3 (ribosomal protein S3) were the five most high-341 
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ly expressed genes in human CNV (Fig. 2F) and Iqgap1, Ptprs (protein tyrosine 342 
phosphatase, receptor type, S), Mertk (MER proto-oncogene tyrosine kinase), Mapk3 343 
(mitogen-activated protein kinase 3) and Sirpa (signal-regulatory protein alpha) in 344 
murine CNV (Fig. 2G). 345 
Figure 2: Transcriptional characterization of human and mouse CNV. (A-B) MA plots illustrating differentially 
expressed genes (DEG) between (A) human CNV (dark green, log2FC > 0.5 and adjusted p < 0.05, n = 1766) 
and human control tissue (light green, log2FC < -0.5 and adjusted p < 0.05, n = 1277) as well as between (B) 
mouse CNV (dark blue, log2FC > 0.5 and adjusted p < 0.05, n = 1196) and mouse control (light blue, log2FC < -
0.5 and adjusted p < 0.05, n = 1183). The top five factors according to the product of log2FC and mean of normal-
ized reads as well as five relevant CNV-associated DEGs known from the literature are labeled. (C+E): Dotplots 
showing the top ten Gene ontology (GO) biological processes, which the significantly upregulated genes in hu-
man (C) and mouse (E) CNV were involved in. The size of the dots represents the number of associated genes 
(count). The adjusted p-value of each GO term is shown by color. The gene ratio describes the ratio of the count 
to the number of all DEGs. (D): Barplot visualizing the percentage of upregulated genes involved in three disease-
relevant biological processes for human and mouse CNV: angiogenesis (GO:0001525, GO:0001568), immune 
response (GO:0006955) and response to wounding (GO:0009611). (F-G): Box plots illustrating the normalized 
reads of the top five expressed genes of two disease-relevant GO terms (GO:0001568, GO:0001816) according 
to mean expression in CNV samples for human (F) and mouse (G). 
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Phylogenetically conserved mediators of CNV 346 
To identify conserved molecular patterns between mice and men, we first determined 347 
genes which were significantly upregulated in CNV membranes of both species when 348 
compared to the respective control tissue (Fig. 3A). The commonly upregulated 349 
genes in human and mouse CNV (n = 95) as well as species-specific DEG (mouse: n 350 
= 151, human: n = 802) are illustrated in Figure 3A. GO analysis revealed that the 95 351 
shared genes were predominantly involved in biological processes such as blood 352 
vessel development/angiogenesis, immune response signal transduction, apoptotic 353 
signaling pathway, myeloid leukocyte activation, leukocyte degranulation and re-354 
sponse to wounding (Fig. 3B). The genes involved in these biological processes are 355 
visualized in Figure 3C. Following this approach, genes such as FN14 (fibroblast 356 
growth factor inducible-14), LGALS3 (galectin 3), AIF1, CTSS (cathepsin S), UNC5B 357 
(unc-5 netrin receptor B), ADAM15, MCAM (melanoma cell adhesion molecule), 358 
CYBB (cytochrome b-245 beta chain), APLNR (apelin receptor), KCNN4 (potassium 359 
calcium-activated channel subfamily N member 4) and UNC93B1 (unc-93 homolog 360 
B1, TLR signaling regulator) were identified as conserved mediators of CNV across 361 
both species (Fig. 3A and 3C). Since transcriptional profiling identified AIF1 (also 362 
known as IBA1) as one of the phylogenetically conserved mediators in human and 363 
mouse CNV, immunohistochemical validation was subsequently performed. These 364 
experiments confirmed significantly increased accumulation of AIF1-positive cells in 365 
the area of CNV in human (Supplement Fig. 1A) and mouse CNV (Supplement Fig. 366 
1C) when compared to the respective control tissue (Supplement Fig. 1B and 1D). 367 
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Figure 3: Phylogenetically conserved mediators of murine and human CNV. (A): Scatter plot illustrating genes 
significantly upregulated in both human and mouse CNV (n = 95, red), only in human CNV (n = 802, green) or 
only in mouse CNV (n = 151, blue) (definition: log2FC > 0.5 and adjusted p < 0.05). The percentile of log2 fold 
change between CNV and control samples for human (x-axis) as well as for mouse (y-axis) was calculated for 
every gene. (B): Dotplot showing the top ten Gene ontology (GO) biological processes, which the 95 significantly 
upregulated genes in both species were involved in (red in A). The number of associated genes is indicated within 
each circle. The adjusted p-value of each GO term is color-coded. The gene ratio describes the ratio of the count 
to the number of all DEG (n = 95). (C): Cnetplot illustrating phylogenetically conserved genes (small circles) asso-
ciated with the top biological processes (large circles) from (B). Color indicates mean log2 fold change of human 
and mouse CNV compared to the respective control group. FN14 was identified as a key factor among the patho-
physiologically most relevant biological processes, with a 4.1-fold increase in human and 1.8-fold increase in 
murine CNV. (D-E): Immunohistochemical validation of FN14 in human CNV (D) as well as in murine laser-
induced CNV (E). (D): a: section of human CNV membrane reveals significant immunoreactivity against FN14. b: 
higher magnification images of FN14 expression in human CNV. Vessels are stained for COL4 (in red) and nuclei 
are counterstained with DAPI (in blue). (E): a: cryosection of murine laser-induced CNV demonstrating high FN14 
immunoreactivity in CNV as well as some expression in physiological retinal vasculature and nuclei, especially in 
ganglion cell and inner nuclei layers. b: higher magnification images of FN14 expression in CNV. Vessels are 
stained for COL4 (in red) and nuclei are counterstained with DAPI (in blue). Abbreviations: CH: choroid, CNV: 
choroidal neovascularization, ONL: outer nuclear layer, RP: retinal pigment epithelium. 
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FN14 and its ligand TWEAK in human and mouse CNV 368 
RNA sequencing identified FN14 as a conserved mediator in human and murine 369 
CNV representing a key factor among the pathophysiologically most relevant biologi-370 
cal processes (Fig. 3C). To validate these findings on a protein level, the expression 371 
of FN14 and its localization in human and murine CNV as well as control tissue were 372 
further investigated by immunohistochemistry. In line with the RNA sequencing re-373 
sults, an increased immunoreactivity against FN14 was observed in human and 374 
mouse CNV (Fig. 3D and 3E) when compared to control tissue (Supplement Fig. 2A 375 
and 2B). Additionally, there was a less pronounced but still detectable immunoreac-376 
tivity in physiological murine choroidal and retinal vessels as well as within the inner 377 
nuclear layer and ganglion cell layer which was not distinctive between CNV and 378 
control samples (Fig. 3E and Supplement Fig. 2B). Negative controls without primary 379 
antibody against FN14 as well as isotype control revealed a high specificity of the 380 
same primary antibody used in human and mouse samples as well as secondary an-381 
tibodies (Supplement Fig. 3). In addition, the concentration of the FN14 ligand 382 
TWEAK (tumor necrosis factor-like weak inducer of apoptosis) (Ameri et al., 2014) 383 
was measured by ELISA. TWEAK was detectable in all human vitreous samples as 384 
well as in the plasma of control and nAMD patients (Supplement Fig. 4A). In both the 385 
control and nAMD groups, vitreous concentrations were 2.6 and 3.0 times higher 386 
than in plasma, respectively, indicating a local accumulation. The TWEAK concentra-387 
tion was comparable between controls and CNV in vitreous (585.0 ± 68.2 pg/ml vs. 388 
498.5 ± 54.7 pg/ml) and plasma samples (222.6 ± 92.6 pg/ml vs. 164.0 ± 33.7 pg/ml) 389 
(Supplement Fig. 4A). In line with the results in human, TWEAK was detected in all 390 
murine samples with comparable concentrations between the CNV and the CNV 391 
group in RPE (139.2 ± 7.8 pg/ml vs. 147.9 ± 7.5 pg/ml) and retinal tissue (80.5 ± 4.0 392 
pg/ml vs. 72.7 ± 4.7 pg/ml) (Supplement Fig. 4B). 393 
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FN14 decoy receptor modulates the cytokine profile in CNV and reduces neo-394 
vascularization 395 
The substantial upregulation of FN14 RNA and protein in human and murine CNV 396 
suggests a conserved role in the pathophysiology of CNV formation. To further inves-397 
tigate this hypothesis, a FN14 decoy receptor, which blocks the interaction between 398 
FN14 and its ligand TWEAK, was injected intravitreally on day 1 after laser CNV in-399 
duction in 10 murine eyes. PBS injected into the partner eye served as control (Fig. 400 
4A). Interestingly, intravitreal injection of FN14 decoy receptor resulted in a signifi-401 
cant reduction (33.1 %, SEM: 6.0, p<0.05) of CNV size compared to PBS injected 402 
eyes (Fig. 4B).  403 
To investigate the effect of the FN14 decoy receptor on the cytokine milieu in CNV, 404 
eight disease-relevant cytokines were measured in CNV tissue at d5 following FN14 405 
decoy receptor treatment at d1. PBS injected into each contralateral eye as well as 5 406 
unlasered eyes served as controls (Fig. 4C). CNV induction was associated with a 407 
significant increase in various cytokines on day 5, among them IL-33, IL-6, CXCL2, 408 
CCL2, MMP-9 and CCL5 (Fig. 4C). Interestingly, in CNV eyes, the FN14 decoy re-409 
ceptor led to a significant reduction of IL-6 when compared to PBS-injected eyes 410 
(29.3 ± 6.9 pg/ml vs. 37.3 ± 4.5 pg/ml, p<0.05, Fig. 4C). IL-33, CXCL2 and CCL5 also 411 
tended to be decreased in the FN14 decoy group, although the differences were not 412 
significant (Fig. 4C). Of note, inhibition of FN14 did not significantly affect VEGF-a 413 
concentration on day 5 after CNV induction (Fig. 4C), suggesting a VEGF-414 
independent anti-angiogenic effect of the FN14 inhibition. 415 
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Figure 4: FN14 decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): 
Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly 
reduced CNV size. Color fundus (CF) and fluorescence angiography (FA) on d7 of representative eyes of the 
FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images 
of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within 
the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, 
CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with 
SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p<0.05, ns: 
not significant. 
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Anti-VEGF therapy has significantly improved visual outcome of patients with neo-416 
vascular AMD during the last years (Bressler et al., 2011; Mitchell et al., 2018). How-417 
ever, about one third of patients show persistent exudation and a slow decrease in 418 
visual acuity despite recurrent anti-VEGF injections (Wecker et al., 2019; Yang et al., 419 
2016). This suggests additional mediators that lead to differentiated vascular mem-420 
branes or subretinal fibrosis in the final stage of the disease. The present study per-421 
formed comparative transcriptomics between human and murine CNV in order to 422 
identify cross species mediators of CNV formation. Following this approach, the 423 
study identifies fibroblast growth factor inducible-14 (FN14) as a so far unrecognized 424 
conserved factor in CNV formation, the inhibition of which results in reduced IL-6 ex-425 
pression and a reduction of CNV size in vivo.  426 
The mouse model of laser-induced CNV has been used extensively in preclinical 427 
studies of nAMD as it mimics the hallmarks and complex sequelae of nAMD including 428 
rupture of Bruch's membrane, immune cell activation, and subsequent acute for-429 
mation of new choroidal blood vessels (Lambert et al., 2013). Our analysis shows 430 
that the transcriptional profile of both human and murine CNV is characterized by 431 
enhanced activation of biological processes such as blood vessel development, actin 432 
cytoskeleton organization, and cytokine production. However, CNV of both species 433 
differed by the predominance of angiogenesis and wound healing processes in hu-434 
man CNV and more pronounced immune processes in murine CNV, which reflects 435 
the more chronic nature of human CNV and the acute and traumatic etiology of CNV 436 
in the mouse model (Lambert et al., 2013). Nevertheless, parallels in the expression 437 
pattern of myeloid cells between mice and humans have been found during CNV 438 
formation in previous studies (Beguier et al., 2020; Schlecht et al., 2020b; Wieghofer 439 
.CC-BY 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 




et al., 2021). Of note, about half of the CNV-associated genes were inversely ex-440 
pressed between human and mouse, indicating distinct differences between the hu-441 
man disease and the mouse model on the transcriptional level. Despite a high num-442 
ber of species-specific factors, 95 DEG were identified that were significantly upregu-443 
lated in both human and murine CNV when compared to the respective control tis-444 
sue. These genes are known mediators of disease-relevant processes such as angi-445 
ogenesis, immune response and wounding. Among them, there were several proan-446 
giogenic factors including APLNR (Hara et al., 2013; Ishimaru et al., 2017; Kasai, 447 
2011; McAnally et al., 2018), LGALS3 (Chen et al., 2017; Jia et al., 2013; Yao et al., 448 
2019), CYBB (Al-Shabrawey et al., 2005; Chan et al., 2013), CTSS (Chen et al., 449 
2010; Fan et al., 2012; Wang et al., 2006), UNC5B (Lejmi et al., 2008), MCAM (Stalin 450 
et al., 2016), ADAM15 (Horiuchi et al., 2003; Hou et al., 2015; Xie et al., 2008) and 451 
KCNN4 (Grgic et al., 2005). In addition to the already known factors, the present 452 
study identifies a plethora of new conserved mediators of CNV development that rep-453 
resent potential therapeutic targets for neovascular AMD. Among these factors, FN14 454 
emerged as a key factor among the most significantly activated and disease-relevant 455 
processes in human and mouse CNV. Immunohistochemistry confirmed an in-456 
creased expression of FN14 protein in the area of human and murine CNV. Besides, 457 
a weaker but still distinct immunoreactivity against FN14 was observed in the murine 458 
inner nuclear layer and ganglion cell layer as well as in physiological retinal and cho-459 
roidal vessels, which is in accordance with the literature (Ameri et al., 2014). The au-460 
thors suggest a baseline expression of FN14 that increases significantly under patho-461 
logical conditions such as the development of CNV (Ameri et al., 2014). The in-462 
creased expression of FN14 under pathological conditions, which is assumed to be 463 
mediated by growth factors, such as FGF, PDGF and VEGF (Burkly et al., 2007), is 464 
well known in the course of various pathologies (Burkly et al., 2007) including the 465 
.CC-BY 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 




formation of retinal neovascularization (Ameri et al., 2014). In addition, the FN14 lig-466 
and TWEAK was distinctly detectable in all human vitreous as well as murine RPE 467 
and retinal samples, further indicating a highly conserved (Burkly et al., 2007) and 468 
potential pathophysiological involvement of the FN14-TWEAK pathway in human and 469 
mouse CNV. Interestingly, we did not observe a significant difference in TWEAK 470 
concentration in the human vitreous as well as murine RPE and retina between CNV 471 
and control groups. These results imply that in CNV, the FN14-TWEAK pathway may 472 
be predominantly regulated by the expression of FN14 rather than by its ligand 473 
TWEAK, which is consistent with the observations for retinal neovascularization 474 
(Ameri et al., 2014) and various other pathologies which an increased expression of 475 
FN14 was reported for (Burkly et al., 2007). It is interesting to note that TWEAK con-476 
centrations were significantly higher in human vitreous compared to the correspond-477 
ing plasma samples of the same patients indicating a distinctive role of the pathway 478 
within the ocular compartment. The FN14-TWEAK axis is known for its proinflamma-479 
tory and proangiogenic properties involved in processes such as endothelial cell pro-480 
liferation (Harada et al., 2002), wound healing and tissue regeneration, contributing 481 
to a variety of pathologies, including retinal neovascularization (Abu El-Asrar et al., 482 
2015; Ameri et al., 2014; Sun et al., 2020), inflammatory diseases (Winkles, 2008) 483 
and cancer (Winkles, 2008). Besides, TNF Receptor Superfamily Member 10a 484 
(TNFRSF10A), belonging to the same TNF receptor superfamily as FN14 485 
(TNFRSF12A), has recently been associated to AMD in a genome wide association 486 
study (Fritsche et al., 2016) and, in accordance with the localization of FN14 ob-487 
served in the present study, was found to be expressed most significantly in vascular 488 
cells of the human retina, as determined by single cell RNA sequencing (Menon et 489 
al., 2019). However, the role of the FN14 signaling pathway has not yet been evalu-490 
ated in CNV.  491 
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To further investigate the pathophysiological significance of the FN14-TWEAK path-492 
way in CNV formation, a FN14 decoy receptor, which blocks the interaction between 493 
FN14 and its ligand TWEAK, was injected intravitreally, resulting in a significantly 494 
reduced CNV size in vivo. Similar results have been obtained for retinal neovascular-495 
ization, where inhibition of the FN14-TWEAK signaling pathway resulted in attenuat-496 
ed vessel formation (Ameri et al., 2014). To gain further insights into the antiangio-497 
genic mechanisms, the cytokine milieu in the CNV tissue was investigated in vivo by 498 
adding or omitting the FN14 decoy receptor. Blocking the FN14-TWEAK-pathway 499 
resulted in a significant reduction of IL-6 concentration in the CNV microenvironment 500 
with a tendency to also decrease IL-33, CXCL2 and CCL5, although the differences 501 
were not significant. These results are in accordance with studies on human astro-502 
cytes (Saas et al., 2000) and orbital fibroblasts (Lee et al., 2018) as well as murine 503 
synovial (Kamata et al., 2006) and mesangial cells (Campbell et al., 2006), which 504 
have shown FN14-TWEAK activation to induce IL-6, CXCL2 and CCL5 secretion, 505 
respectively. These results may indicate that FN14 influences CNV development, at 506 
least in part, through modulation of IL-6, although this does not exclude other soluble 507 
factors to be regulated by the treatment with the FN14 decoy receptor. In conse-508 
quence, targeting FN14 may be a novel promising therapeutic strategy for the treat-509 
ment of CNV. Of note, clinical studies evaluating antibody-based inhibitors of the 510 
FN14-TWEAK signaling pathway have demonstrated a high level of tolerability 511 
(Wisniacki et al., 2013) and a significant reduction of FN14-TWEAK signaling in hu-512 
mans (Meulendijks et al., 2016), further supporting a potential therapeutic applicabil-513 
ity for neovascular AMD. 514 
Taken together, this study characterizes the transcriptome of human and mouse 515 
CNV membranes in an unpreceded and unbiased manner and identifies FN14 as a 516 
so far unrecognized phylogenetically conserved mediator of CNV formation. Intravi-517 
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treal injection of an FN14 decoy receptor significantly reduced IL-6 expression and 518 
CNV size in vivo. FN14 is thus suggested as a promising novel therapeutic target for 519 
neovascular AMD, which may potentially be beneficial in patients with exudative 520 
AMD.  521 
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Supplementary Figure 1: Immunohistochemical validation of AIF1 in human (A-B) and mouse (C-D) CNV (A+C) and control 
tissue (B+D). (A): a: sections of human CNV membranes demonstrating accumulation of AIF1 positive cells (in green) at 
sites of CNV stained for COL4 (in red). b: higher magnification images of AIF1-positive cells in the area of CNV. Vessels 
are stained for COL4 (in red) and nuclei are counterstained with DAPI (in blue). (B): control tissue shows significantly lower 
number of AIF1-positive cells when compared to CNV. (C): a: cryosections of mouse laser-induced CNV demonstrating 
accumulation of AIF1-positive cells (in green) in the area of CNV stained for COL4 (in red). Right panel: higher magnification 
images of AIF1-positive cells in the retina (upper panel) as well as in the area of CNV (lower panel). Vessels are stained for 
COL4 (in red) and nuclei are counterstained with DAPI (in blue). (D): significantly lower number of AIF1-positive cells in 
murine control tissue. Abbreviations: CH: choroid, CNV: choroidal neovascularization, ONL: outer nuclear layer, RP: retinal 
pigment epithelium. 
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Supplementary Figure 2: FN14 staining in human (A) and mouse (B) control tissue revealing significantly lower immuno-
reactivity in RPE/choroid (c) compared to CNV (Fig. 3D and E). Vessels and CNV are stained for COL4 (in red) and nuclei 
are counterstained with DAPI (in blue). Abbreviations: CH: choroid, ONL: outer nuclear layer, RP: retinal pigment epithelium. 
The areas within the white continuous line are shown in higher magnification to the right.  
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Supplementary Figure 3: (A+B) FN14 negative control as well as (C) FN14 isotype control in human CNV (A) as well as 
in laser-induced CNV (B-C) revealed high specificity of primary and secondary antibodies. Vessels are stained for COL4 (in 
red) and nuclei are counterstained with DAPI (in blue). Abbreviations: CH: choroid, CNV: choroidal neovascularization, ONL: 
outer nuclear layer, RP: retinal pigment epithelium. 
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Supplementary Figure 4: (A): Vitreous and plasma concentration of TWEAK in neovascular AMD and control patients as 
well as in (B) murine RPE and retina samples in CNV and control group as determined by TWEAK ELISA. Data is shown 
as mean with SEM. Plasma samples in humans were taken at the time of surgery. 
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